ADAKVEO
ADAKVEO (crizanlizumab-tmca) is an FDA-approved monoclonal antibody infusion therapy used to help reduce the frequency of vaso-occlusive crises (VOCs) in patients with sickle cell disease aged 16 years and older. Each sterile, preservative-free 1×10 mL single-dose vial is formulated for intravenous infusion under professional supervision. ADAKVEO works by blocking P-selectin, a cell-adhesion molecule involved in the clumping of blood cells that causes painful VOCs.
InfusionMed USA, located in Carrollton, Texas, supplies ADAKVEO vials to licensed infusion centers, hospitals, and mobile IV therapy providers throughout Dallas, Frisco, McKinney, The Colony, Lewisville, Plano, and nearby North Texas regions. We maintain rigorous cold-chain handling, FDA-compliant storage, and fast, reliable delivery for every order.
Available exclusively for licensed healthcare professionals and infusion facilities.
Download Form